2Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin, 2010, 60(5) : 277 -300.
3Jung KW, Park S, Won Y J, et al. Prediction of cancer incidence and mortality in Korea. Cancer Rcs Treat, 2011, 43 ( 1 ) : 12 - 18.
4Signorelli M, Caspani G, Bonazzi C, et al. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG,2009,116(1):114-118.
5Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol, 2007,109 ( 3 ) : 655 - 662.
6Ota T, Yoshida M, Kimura M, et al. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer, 2005, 15(4) :657 -662.
7Park JY, Kim DY, Kim JH, et al. Long-term oneologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002 ). Eur J Cancer, 2013, 49(4) :868 -874.
8Gallos 1D, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and recta-analysis. Am J Obstet Gynecol, 2012, 207(4): 266. el - el2.
9Minig L, Franchi D, Boverl S, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endnmetrlal precancers and well-differentlated early endometrial carcinoma in young women. Ann Oncol, 2011, 22 (3) : 643 - 649.
10Laurelli G, Di Vagno G, Scaffa C, et al. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol, 2011 , 120(1) : 43 -46.
